MedVax Technologies, Inc., a biopharmaceutical company, has announced that Robert Brooks, Founder and Chief Executive Officer, has accepted an invitation to present at the 7th Annual Biotech Showcase
MIAMI, FL - December 1, 2014 - MedVax Technologies, Inc., a biopharmaceutical company, has announced that Robert Brooks, Founder and Chief Executive Officer, has accepted an invitation to present at the 7th Annual Biotech Showcase.
MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, has announced that Robert Brooks, Founder and Chief Executive Officer, has accepted an invitation to attend the 7th Annual Biotech Showcase investor and partnering conference on January 12 - 14, at the Parc 55 Wyndham - Union Square, San Francisco, CA.
About MedVax Technologies,Inc.
MedVaxTechnologies,Inc. (www.medvax.net) is a clinical-stage biopharrnaceutical company focused on developing cancer vaccine immunotherapies. TheCompany is developing two lead products of cancer vaccines, focused on Antigen Presenting Cells (APC's) of the immune system. MX-225 is anautologous P53 dendritic cell vaccine that recently completed PhaseII (a) clinical trials in Small Cell Lung Cancer and an ongoing Phase II trial in Breast cancer at Moffitt Cancer Center. MX-402 is anon-autologous "off-the-shelf" HER-2 Peptide vaccine currently completing a 2nd Phase I clinical trial in solid tumors at the James Cancer Center, Ohio State University.
Forward Looking Statement
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 that reflect MedVax's current expectations about its future results, performance, prospects and opportunities. Where possible, MedVax has tried to identify these forward-looking statements by using words such as"anticipates", 'believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. MedVax cannot assure you that it will be able to successfully develop or commercialize these products or its business strategy will be successful. MedVax assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, changes in circumstances or for any other reason.
MedVax Technologies, Inc.
VP, Business Administration & Public Relations
(305) 371-2301 (Office)
(305) 371-2304 (Fax)
Source: MedVax Technologies, Inc.